Table 1. Patient characteristics before and after propensity score matching (PSM).
| Objects | Entire patients (n = 239) |
PSM (23 pairs) |
||||
|---|---|---|---|---|---|---|
| SLT | PLT | p | SLT | PLT | p | |
| Age (y) Mean ± SD | 47.79 ± 8.64 | 50.45 ± 9.24 | 0.149 | 47.70 ± 9.14 | 50.35 ± 7.61 | 0.572 |
| Gender Male/female | 24/4 | 179 /32 | 1 | 19/4 | 21/2 | 0.665 |
| AFP (mg/mL) median (IQR) | 166.2 (13.47~398.20) | 107.7 (14.08~397.80) | 0.714 | 170.0 (22.70~522.40) | 166.2 (20.80~502.80) | 0.982 |
| CA19–9 (U/mL) median (IQR) | 20.40 (8.50~37.15) | 36.7 (18.60~56.90) | <0.001 | 20.4 (7.40~33.20) | 36.70 (12.17~45.27) | 0.141 |
| Tumor status | 0.548 | 0.238 | ||||
| Within Milan No. (%) | 13 (46.43) | 113 (53.55) | 9 (39.13) | 14 (60.87) | ||
| Over Milan No. (%) | 15 (53.57) | 98 (46.45) | 14 (60.87) | 9 (39.13) | ||
| HBsAg (+) No. (%) | 25 (89.29) | 199 (94.31) | 0.395 | 21 (91.30) | 21 (91.30) | 1.000 |
| HBV DNA (+) No. (%) | 9 (32.14) | 133 (63.03) | 0.001 | 8 (39.13) | 13 (43.48) | 0.236 |
| HCV (+) | 1 (3.57) | 4 (1.90) | 0.467 | 1 (4.35) | 1 (4.35) | 1 |
| Child-Pugh No. (%) | 0.026 | 0.089 | ||||
| A | 17 (60.71) | 76 (36.02) | 16 (69.57) | 9 (39.13) | ||
| B | 6 (21.43) | 97 (45.97) | 5 (21.74) | 12 (52.17) | ||
| C | 5 (17.86) | 38 (18.01) | 2 (8.70) | 2 (8.70%) | ||
| Rapamicin (+) No. (%) | 14 (50%) | 86 40.76% | 0.416 | 14 (60.97) | 12 (52.17) | 0.767 |